Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vipivotide Tetraxetan SCHEMBL20180896 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21881849 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21872782 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24729006 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21316439 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24612683 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL22313039 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL24729005 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL21501570 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Vipivotide Tetraxetan SCHEMBL29648484 | 1.00 | FOLH1 (1.00) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| EP-3763394-B1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | ISOTOPIA MOLECULAR IMAGING LTD (IL) | 2023-11-08 | — | — | EP | disclosed |
| EP-3763394-B1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | ISOTOPIA MOLECULAR IMAGING LTD (IL) | 2023-11-08 | — | — | EP | disclosed |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023152671-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 225-ACTINIUM-LABELLED COMPLEX AND A BISMUTH SEQUESTERING AGENT | NOVARTIS AG (CH) | 2023-08-17 | — | — | WO | disclosed |
| US-11547767-B2 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES (MX) | 2023-01-10 | — | — | US | disclosed |
| WO-2022106629-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | FIVE ELEVEN PHARMA INC (US) | 2022-04-28 | — | — | US | disclosed |
| CN-114364405-A | Prostate Specific Membrane Antigen (PSMA) inhibitors as diagnostic agents and radionuclide therapeutics | 五一一制药股份有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20200138985-A1 | KIT FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd. (IL) | 2020-05-07 | — | — | US | disclosed |
| US-10471160-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2019-11-12 | — | — | US | disclosed |
| US-10398791-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2019-09-03 | — | — | US | disclosed |
| US-20190015531-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| CN-109134602-A | A kind of method for preparing solid phase of efficient prostate-specific membrane antigen ligand PSMA-617 | 兰州大学 | 2019-01-04 | — | — | CN | disclosed |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | FIVE ELEVEN PHARMA INC. | 2017-07-06 | — | — | US | disclosed |
| US-20160256579-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd. (IL) | 2016-09-08 | — | — | US | disclosed |
| US-20160256579-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd. (IL) | 2016-09-08 | — | — | US | disclosed |
| EP-3064224-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd (IL) | 2016-09-07 | — | — | EP | disclosed |
| EP-3064224-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | Isotopia Molecular Imaging Ltd (IL) | 2016-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471160-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-20170189568-A1 | UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THERAPY | KLK3, FOLH1, UTS2R | FOLH1 2/4885 |
| US-20160256579-A1 | METHOD FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | KLK3, FOLH1, PSMA7 | FOLH1 2/4885 |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FOLH1 74/4885 |
| US-20200138985-A1 | KIT FOR LABELING A PROSTATE-SPECIFIC MEMBRANE ANTIGEN LIGAND WITH A RADIOACTIVE ISOTOPE | KLK3, FOLH1, KIT | FOLH1 2/4885 |
| US-20230302164-A1 | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | FOLH1 3/4885 |
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, BPHL | FOLH1 1/4885 |
| US-20220125959-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS AS DIAGNOSTIC AND RADIONUCLIDE THERAPEUTIC AGENTS | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-10398791-B2 | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA1 | FOLH1 2/4885 |
| US-20190015531-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FOLH1 74/4885 |
| US-11547767-B2 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | KLK3, EPS15, CD99 | FOLH1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.